Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
06 déc. 2023 07h00 HE
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis ...
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
22 nov. 2023 09h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
09 nov. 2023 07h00 HE
|
Optinose, Inc.
Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D...
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
27 oct. 2023 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the 2023 Cantor Global Healthcare Conference
22 sept. 2023 09h01 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
10 août 2023 07h00 HE
|
Optinose, Inc.
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023...
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
27 juil. 2023 07h00 HE
|
Optinose, Inc.
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 ...
Optinose to Present at the Jefferies Healthcare Conference
02 juin 2023 13h00 HE
|
Optinose, Inc.
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
11 mai 2023 07h00 HE
|
Optinose, Inc.
Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company...
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
04 mai 2023 07h00 HE
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...